Researchers found that 25.3% of 1,632 diabetic macular edema patients did not return for a follow-up visit within one year of receiving an anti-vascular endothelial growth factor injection for nonproliferative diabetic retinopathy. The findings in Ophthalmology Retina showed that lower income, worse baseline visual acuity, and those of Hispanic or other or unknown ethnicity were more likely to be lost to follow-up.
Study IDs risk factors tied to DME follow-up noncompliance
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.